A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
Phase 1
75
about 3.7 years
18+
15 sites in CA, CT, FL +10
What this study is about
Researchers are testing whether TSC-100 or TSC-101 are safe and effective when given to people with Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndromes (MDS) who are receiving a stem cell transplant from a donor. The trial will involve different doses of TSC-100 or TSC-101, along with standard treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Control
- 2.Take SOC + TSC-100
- 3.Take SOC + TSC-101
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Occurrence of adverse events
Secondary: Comparison of disease free survival in patients versus the control arm, Comparison of overall survival between patients and control arm, Disease-free survival in patients versus the control arm at 18 months, defined as the time from date of transplant to death or relapse/progression, whichever comes first. Participants alive and disease free will be censored at the last follow-up.
Oncology